Limin Group planning fundraising for emamectin benzoate, fosetyl-aluminium projects

On 25th February, 2021, the Limin Group Co., Ltd. made several announcements related to fundraising to support an annual 12,000-ton fosetyl-aluminium technical upgrading project, a 10,000-ton water-based environmentally friendly formulation manufacturing project, a newbuild 500-ton emamectin benzoate facility, and an energy conservation project, as well as for attaining working capital input.

The details of these major project are as follows:

1. An annual 12,000-ton fosetyl-aluminium technical upgrading

The Limin Group currently has an annual production capacity of 5,000 tons of fosetyl-aluminium technical, which has been running at saturated load. The company’s fosetyl-aluminium customers include well-known multinationals, domestic prime formulators and terminal users. The Limin Group has predicted a future increase in fosetyl-aluminium demand, which cannot be fulfilled by its existing capacity. After the completion of the upgrade, fosetyl-aluminium production capacity is expected to reach 12,000 tons annually, which will be a significant rise over existing capacity. The production process of fosetyl-aluminium is clean and green, enabling the recycling of waste leading towards zero emissions, in line with the future industry development trend.

2. An annual 10,000-ton water-based environmentally friendly formulation project

The Limin Group’s water-based environmentally friendly formulation capacity is currently low. According to its development strategy and market demand, it is prepared to increase its production of environmentally friendly pesticide formulations to meet safety and environmental requirements. After the completion of its annual 10,000-ton water-based environmentally friendly formulation project, the Limin Group’s production capacity formulations will greatly increase, considerably enhancing its competitiveness in the water-based environmentally friendly formulation market.

3. Newbuild annual 500-ton emamectin benzoate facility 

The Limin Group currently has an emamectin benzoate production capacity of 300 tons, which has been running at saturated load but cannot fully meet demand. Veyong, a subsidiary of the company, is one of the earliest emamectin manufacturers in China, being a national emamectin industry leader supported by a strong technical and sales team and serving its stable customers at home and abroad. On top of the existing capacity of 300 tons, the newbuild will add an annual capacity of 500 tons of emamectin benzoate. With this expanded capacity, the company will be in a better position to meet the needs of customers.